Evolent Health (NYSE:EVH) Stock Price Up 8.1% – Still a Buy?

Posted by George Bondi on Oct 20th, 2026

Evolent Health, Inc (NYSE:EVH – Get Free Report)’s share price was up 8.1% on Tuesday. The stock traded as high as $4.80 and last traded at $4.8450. Approximately 238,234 shares were traded during mid-day trading, a decline of 92% from the average session volume of 2,905,948 shares. The stock had previously closed at $4.48.

Analysts Set New Price Targets

EVH has been the topic of several analyst reports. Canaccord Genuity Group decreased their price target on shares of Evolent Health from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. TD Cowen upped their price target on shares of Evolent Health from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Weiss Ratings lowered shares of Evolent Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. JPMorgan Chase & Co. lifted their target price on shares of Evolent Health from $5.00 to $6.00 and gave the company an “overweight” rating in a research note on Tuesday, August 18th. Finally, Truist Financial dropped their target price on Evolent Health from $7.00 to $6.00 and set a “hold” rating for the company in a report on Wednesday, August 12th. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $5.96.

View Our Latest Analysis on EVH

Evolent Health Stock Performance

The company has a debt-to-equity ratio of 2.52, a current ratio of 1.24 and a quick ratio of 1.24. The company’s 50-day moving average price is $4.17 and its two-hundred day moving average price is $4.14. The company has a market capitalization of $548.91 million, a price-to-earnings ratio of -1.06 and a beta of 1.02.

Evolent Health (NYSE:EVH – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The technology company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.03. Evolent Health had a negative net margin of 24.08% and a negative return on equity of 4.27%. The company had revenue of $484.50 million during the quarter, compared to analyst estimates of $597.70 million. During the same quarter in the prior year, the business earned ($0.10) earnings per share. The firm’s revenue for the quarter was up 46.9% on a year-over-year basis. On average, equities research analysts anticipate that Evolent Health, Inc will post -0.25 EPS for the current fiscal year.

Insider Activity

In other Evolent Health news, President Daniel Mccarthy sold 65,892 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $5.00, for a total value of $329,460.00. Following the transaction, the president directly owned 655,133 shares in the company, valued at approximately $3,275,665. This trade represents a 9.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.48% of the stock is currently owned by insiders.

Institutional Trading of Evolent Health

A number of large investors have recently modified their holdings of the company. R Squared Ltd acquired a new stake in Evolent Health during the 1st quarter worth about $26,000. Royal Bank of Canada grew its holdings in shares of Evolent Health by 51.6% in the first quarter. Royal Bank of Canada now owns 25,161 shares of the technology company’s stock valued at $57,000 after purchasing an additional 8,563 shares in the last quarter. Wealthfront Advisers LLC lifted its position in shares of Evolent Health by 40.8% during the 1st quarter. Wealthfront Advisers LLC now owns 28,083 shares of the technology company’s stock worth $64,000 after purchasing an additional 8,136 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new stake in shares of Evolent Health in the second quarter valued at about $78,000. Finally, Y Intercept Hong Kong Ltd lifted its stake in shares of Evolent Health by 36.0% in the first quarter. Y Intercept Hong Kong Ltd now owns 60,847 shares of the technology company’s stock valued at $139,000 after purchasing an additional 16,098 shares during the period.

About Evolent Health

(Get Free Report)

Evolent Health, Inc is a healthcare services and technology company that helps health plans and providers manage specialty care and transition to value-based models. Its offerings are designed to coordinate care, improve clinical outcomes and support more predictable healthcare costs across complex medical conditions.

The company provides technology-enabled administrative, clinical and analytical services for areas such as oncology, cardiology, musculoskeletal care and other specialty-care categories.